This work will provide a historical perspective on tumor immunotherapy, discuss fundamental mechanisms of failed tumor rejection, look at passive strategies to boost anti-tumor immunity, as well as have an in-depth look at active strategies to boost anti-tumor immunity.
In-depth discussion over the entire field of tumor immunotherapy, past, present, and future
Comprehensive list of contributors discussing a broad range of topics
The field is very active with many researchers working with immunotherapy and cell biology
This volume is a comprehensive discussion of the major factors affecting tumor immunology and a discussion of all major anti-cancer immunotherapeutic agents approved by the Food and Drug Administration of the United States and by European agencies. Many promising but unapproved agents in clinical trials are also discussed, as are key pre-clinical developments. The major challenges and intellectual issues facing investigators developing novel immunotherapeutics are discussed in detail as are conceptual developments influencing current and future treatment strategies.
Each chapter begins by defining all relevant key terms and concepts and provides pertinent background information so that the text will be accessible to newcomers to the field as well as to the expert. This text book should provide an excellent reference resource for investigators in tumor immunology, life sciences students, drug developers designing novel anti-cancer immunotherapeutics, and to other individuals with some scientific training wishing to gain a better understanding of the field of tumor immunotherapy.
Although the field is evolving rapidly, we have taken pains to ensure that information was as up to date as possible as the text went to press.
Introduction.- Historical Perspectives and Current Trends in Cancer Immunotherapy.- T cell and Antigen-Presenting Cell Subsets in the Tumor Microenvironment.- Adoptive T Cell Transfer.- Dendritic Cell-Based Cancer Immunotherapy: Achievements and novel concepts.- Peptide and Protein-based Cancer Vaccines.- Antigen Targeting to Dendritic Cells for Cancer Immunotherapy.- Cytokines in the Treatment of Cancer.- Immune Co-signaling to Treat Cance.- Managing Regulatory T cells.- Myeloid-Derived Suppressor Cells in Cancer: Mechanisms and therapeutic perspectives .- Antibodies as Cancer Immunotherapy.- Targeted Toxins in Cancer Immunotherapy.- Miscellaneous Approaches and Considerations: TLR agonists and other inflammatory agents, anti-chemokine agents, infectious agents, tumor stroma targeting, age and sex effects, and miscellaneous small molecules.- Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies.- Monitoring Antigen-Specific Responses in Clinical Trials of Immunotherapy.- Index